Literature DB >> 3056253

Endogenous active efflux of norfloxacin in susceptible Escherichia coli.

S P Cohen1, D C Hooper, J S Wolfson, K S Souza, L M McMurry, S B Levy.   

Abstract

Escherichia coli was shown to have an energy-dependent reduced uptake of the fluoroquinolone antimicrobial agent norfloxacin. Studies of everted inner membrane vesicles suggested that this reduced accumulation involved a carrier-mediated norfloxacin active efflux generated by proton motive force with an apparent Km of 0.2 mM and a Vmax of 3 nmol min-1 mg of protein-1. Other hydrophilic, but not hydrophobic, quinolones competed with norfloxacin for transport. Porin (OmpF)-deficient E. coli cells were twofold less susceptible to norfloxacin and showed twice as much energy-dependent reduction in drug uptake. However, active efflux assayed in everted vesicles from the OmpF strain was unchanged compared with that in the parental strain. These findings suggest that in the OmpF mutant decreased outer membrane permeability, combined with active efflux across the inner membrane, in some manner results in decreased steady-state uptake of norfloxacin and lowered drug susceptibility.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056253      PMCID: PMC172374          DOI: 10.1128/AAC.32.8.1187

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Accumulation of enoxacin by Escherichia coli and Bacillus subtilis.

Authors:  J Bedard; S Wong; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

2.  Norfloxacin resistance in a clinical isolate of Escherichia coli.

Authors:  H Aoyama; K Sato; T Kato; K Hirai; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Mutants of Escherichia coli requiring methionine or vitamin B12.

Authors:  B D DAVIS; E S MINGIOLI
Journal:  J Bacteriol       Date:  1950-07       Impact factor: 3.490

5.  Expression of a multidrug-resistance gene in human tumors and tissues.

Authors:  A T Fojo; K Ueda; D J Slamon; D G Poplack; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

6.  H+/ATP stoichiometry of proton pumps from Neurospora crassa and Escherichia coli.

Authors:  D S Perlin; M J San Francisco; C W Slayman; B P Rosen
Journal:  Arch Biochem Biophys       Date:  1986-07       Impact factor: 4.013

Review 7.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

8.  Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli.

Authors:  K Hirai; H Aoyama; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

9.  Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.

Authors:  K Hirai; H Aoyama; S Suzue; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

10.  Reversal of chloroquine resistance in Plasmodium falciparum by verapamil.

Authors:  S K Martin; A M Oduola; W K Milhous
Journal:  Science       Date:  1987-02-20       Impact factor: 47.728

View more
  72 in total

Review 1.  Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors:  S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 3.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

Review 4.  Active efflux mechanisms for antimicrobial resistance.

Authors:  S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

5.  Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid.

Authors:  N Moniot-Ville; J Guibert; N Moreau; J F Acar; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

6.  Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424.

Authors:  J Pace; A Bertasso; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

7.  Mechanisms that may account for differential antibiotic susceptibilities among Coxiella burnetii isolates.

Authors:  M R Yeaman; O G Baca
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

8.  Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin.

Authors:  J Bedard; S Chamberland; S Wong; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

9.  Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa.

Authors:  R A Celesk; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 10.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.